Oliver Luxxe Assets LLC Increases Stake in CVS Health Corporation $CVS

Oliver Luxxe Assets LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS) by 16.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 103,446 shares of the pharmacy operator’s stock after purchasing an additional 14,447 shares during the quarter. CVS Health makes up approximately 1.2% of Oliver Luxxe Assets LLC’s portfolio, making the stock its 23rd biggest position. Oliver Luxxe Assets LLC’s holdings in CVS Health were worth $8,209,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. raised its holdings in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the last quarter. Corundum Trust Company INC purchased a new position in shares of CVS Health in the third quarter valued at about $29,000. GoalVest Advisory LLC bought a new position in shares of CVS Health during the fourth quarter valued at about $32,000. Finally, Front Row Advisors LLC raised its stake in shares of CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 371 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS’s board declared a quarterly dividend of $0.665/share (payable May 4; record April 23), a cash-return signal that can support the share price. CVS Health declares quarterly dividend
• Positive Sentiment: Brokerages’ consensus rating sits at “Moderate Buy,” providing analyst support amid volatility. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Positive Sentiment: CVS announced a $2.24M investment to expand health access in west Charlotte — a community-health initiative that highlights growth of care-delivery and outreach programs. CVS Health invests $2.24 million in west Charlotte health initiative
• Neutral Sentiment: Media roundup and dividend-focused pieces are covering CVS alongside other dividend payers — keeps the name in income-focused investor conversations but is unlikely to move shares materially. Dividend roundup: JPMorgan Chase, Micron Technology, CVS Health, Broadcom, and more
• Neutral Sentiment: Coverage calling CVS a “trending” stock and roundups on healthcare stock picks keep investor attention but are mixed in tone — watch for conviction from earnings/forward guidance. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Company exec discussed AI policy and quality initiatives — signals operational focus but not an immediate catalyst. CVS Health/Aetna executive discusses company AI policy and the harder truth about quality
• Negative Sentiment: Bernstein Litowitz filed a racketeering class action against CaremarkPCS and CVS alleging fraud of PBM customers — this is a material legal overhang that could prompt costs, fines or settlements. Bernstein Litowitz Berger & Grossmann Announces Filing of Racketeering Class Action Against CaremarkPCS and CVS Health Corporation
• Negative Sentiment: Tennessee legislation targeting pharmacy benefit managers (PBMs) could force store closures — state estimates say 100+ CVS locations might be affected, raising local revenue and access risks. TN bill targeting pharmacy benefit managers could threaten closure of 100+ CVS stores in the state
• Negative Sentiment: Lawmakers and a U.S. Representative (Aftyn Behn) are calling for investigations and have heard conflicting testimony about CVS claims that pharmacies will close — increased regulatory scrutiny and political risk. Rep. Aftyn Behn calls for an investigation into CVS claims that pharmacies are closing
• Negative Sentiment: Local reporting and commentary examine whether lawmakers can curb CVS/PBM influence on drug pricing — signals broader regulatory attention on CVS’s PBM business. Could lawmakers crack CVS’s grip on the prescription drug supply chain?

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Truist Financial set a $100.00 target price on CVS Health in a research note on Wednesday, December 10th. The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Argus cut their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. TD Cowen restated a “buy” rating on shares of CVS Health in a report on Friday, March 13th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Twenty investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.05.

CVS Health Stock Performance

Shares of CVS opened at $71.58 on Friday. The company has a 50-day simple moving average of $77.48 and a two-hundred day simple moving average of $77.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The firm has a market capitalization of $91.07 billion, a PE ratio of 51.87, a price-to-earnings-growth ratio of 0.75 and a beta of 0.49. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health’s payout ratio is currently 192.75%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.